Cardio‐Renal Biomarker Soluble Urokinase‐Type Plasminogen Activator Receptor Is Associated With Cardiovascular Death and Myocardial Infarction in Patients With Coronary Artery Disease Independent of Troponin, C‐Reactive Protein, and Renal Function
Authors:
Open Access
- 21 April 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 9 (8) , e015452
Abstract
Background: Risk stratification among patients with coronary artery disease ( CAD ) is of considerable interest due to the potential to guide secondary preventive therapies. Thus, we evaluated the predictive value of soluble urokinase‐type plasminogen activator receptor (su PAR ) levels for cardiovascular mortality and nonfatal myocardial infarction in patients with CAD . Methods and Results: Plasma levels of su PAR were measured in a cohort of 1703 patients with documented CAD as evidenced by coronary angiography—including 626 patients with acute coronary syndrome and 1077 patients with stable angina pectoris. Cardiovascular death and/or nonfatal myocardial infarction were defined as main outcome measures. During a median follow‐up of 3.5 years, su PAR levels reliably predicted cardiovascular death or myocardial infarction in CAD , evidenced by survival curves stratified for tertiles of su PAR levels. In Cox regression analyses, the hazard ratio for the prediction of cardiovascular death and/or myocardial infarction was 2.19 ( P P P =0.022) in the overall cohort and 2.22 ( P =0.005) in the acute coronary syndrome cohort. Conclusions: Su PAR has a strong and independent prognostic value in secondary prevention settings, and thereby might represent a valuable biomarker for risk estimation in CAD .Keywords
This publication has 33 references indexed in Scilit:
- Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic reviewIntensive Care Medicine, 2012
- Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study)European Heart Journal, 2010
- Modification of kidney barrier function by the urokinase receptorNature Medicine, 2007
- Development and Validation of a Multiplex Add-On Assay for Sepsis Biomarkers Using xMAP TechnologyClinical Chemistry, 2006
- Structure of Human Urokinase Plasminogen Activator in Complex with Its ReceptorScience, 2006
- Inflammation, Atherosclerosis, and Coronary Artery DiseaseNew England Journal of Medicine, 2005
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationNew England Journal of Medicine, 2004
- Glutathione Peroxidase 1 Activity and Cardiovascular Events in Patients with Coronary Artery DiseaseNew England Journal of Medicine, 2003
- Immune Mechanisms in AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2001
- Proportional hazards tests and diagnostics based on weighted residualsBiometrika, 1994